Clinical Trials Logo

Clinical Trial Summary

Acute diarrhea and acute colitis of infectious origin are common reasons for consultation at the emergency department. The current etiological diagnostic approach is limited to the determination of markers of inflammation, such as CRP and blood leukocytes, which lack specificity and sensitivity for bacterial infection. The stool culture can detect bacterial pathogens in the stool with a result at least 48 hours later and a positivity rate <50%. This study will describe the procalcitonin (PCT) concentrations (a biomarker of bacterial infection) in this population to evaluate its usefulness depending on the viral or bacterial etiology identified by stool multiplex gastro-intestinal PCR panel (GI panel) and stool culture. The investigators hypothesize that PCT levels will be higher if the GI panel or the stool culture identifies a bacteria or a parasite, as it is the case in respiratory tract infections. If there is a detection of a virus by the GI panel or both the stool culture and the GI panel are negative, the investigators expect that PCT values will be lower or negative. the investigators will include the patients admitted to the ED with a suspicion of infectious diarrhea or acute colitis in order to have a large representative panel of infectious diarrhea etiologies. Only the patients having a blood sample prescribed as the routine care will be included. The blood sample is useful for dosing CRP and whole blood cell count (WBC), which are part of current biologic analyses performed in this context. After getting the patient's consent, the investigator will add the PCT dosage in blood sampling and will ask the patient to provide a stool sample, in order to have a stool culture and to perform an extended investigation for the pathogens through multiplex PCR technology (Filmarray ®GI panel). The physician will be asked if all these results (the ones ordered currently together with the dosage of PCT and the GI panel) will change his/her decision to start an antibiotic. Patients will receive a phone call at day 15 after their initial admission in the emergency department and will be asked if he/she has consulted a new physician or if a new treatment by antibiotics was started. Data collection procedures: Data from the medical file will be collected by the investigators and the emergency department clinical research assistant. All the data will be pseudonymized. The collection will be done at the day of admission in the emergency department and after the phone interview at Day15.


Clinical Trial Description

Acute diarrhea and acute colitis of infectious origin are common reasons for consultation at the emergency department. The current etiological diagnostic approach is limited to the determination of markers of inflammation, such as CRP and blood leukocytes, which lack specificity and sensitivity for bacterial infection. The stool culture can detect bacterial pathogens in the stool with a result at least 48 hours later and a positivity rate <50%. This study will describe the procalcitonin (PCT) concentrations (a biomarker of bacterial infection) in this population to evaluate its usefulness depending on the viral or bacterial etiology identified by stool multiplex gastro-intestinal PCR panel (GI panel) and stool culture. The investigators hypothesize that PCT levels will be higher if the GI panel or the stool culture identifies a bacteria or a parasite, as it is the case in respiratory tract infections. If there is a detection of a virus by the GI panel or both the stool culture and the GI panel are negative, the investigators expect that PCT values will be lower or negative. The investigators will include the patients admitted to the ED with a suspicion of infectious diarrhea or acute colitis in order to have a large representative panel of infectious diarrhea etiologies. Only the patients having a blood sample prescribed as the routine care will be included. The blood sample is useful for dosing CRP and whole blood cell count (WBC), which are part of current biologic analyses performed in this context. After getting the patient's consent, the investigator will add the PCT dosage in blood sampling and will ask the patient to provide a stool sample, in order to have a stool culture and to perform an extended investigation for the pathogens through multiplex PCR technology (Filmarray ®GI panel). The physician will be asked if all these results (the ones ordered currently together with the dosage of PCT and the GI panel) will change his/her decision to start an antibiotic. Patients will receive a phone call at day 15 after their initial admission in the emergency department and will be asked if he/she has consulted a new physician or if a new treatment by antibiotics was started. Data collection procedures: Data from the medical file will be collected by the investigators and the emergency department clinical research assistant. All the data will be pseudonymized. The collection will be done at the day of admission in the emergency department and after the phone interview at Day15. Statistical justification for sample size: This will be a pilot study to describe the results of PCT concentration and multiplex GI panel. As to our knowledge, there is no published study reporting PCT concentrations in this population. This preclude a sample, size calculation. The investigators will include as much patients as possible during one year in order to cover the epidemiological seasonal variations and to obtain a convenient sample of at least 100 patients. Statistical methods description: Clinical and biological data will be reported as median and interquartile range or mean +/- SD. PCT values will be reported as median and IQR, respectively if a there is a viral infection, a documented infection (bacterium or parasite) or no pathogen identified by GI panel and/or stool culture (bacteria). Patient's characteristics and PCT results will be compared in all groups, using as a reference, the group where no pathogen is observed. A sub-group analysis will be performed on colitis and acute diarrhea respectively, to find out if there is any difference with the variables analyzed as both pathologies are not managed in the same way. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04237181
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date March 9, 2020
Completion date December 23, 2021

See also
  Status Clinical Trial Phase
Completed NCT04039828 - Zinc Sulfate Acceptability N/A
Completed NCT03943654 - Improving Nighttime Access to Care and Treatment (Part 2)
Completed NCT01577043 - Efficacy of Racecadotril in Acute Watery Diarrhea in Children Phase 4
Not yet recruiting NCT03598010 - Safety, Tolerability and Preliminary Efficacy of Lenodiar Pediatric in Diarrhea N/A
Completed NCT03684538 - Efficacy Of Probiotics vs. Zinc vs. Probiotics-Zinc Combination On Acute Diarrhea In Children N/A
Terminated NCT02817165 - Probiotics for the Prevention of Antibiotic-Associated Diarrhea N/A
Completed NCT05345028 - Boswellia Serrata Extract in Acute Diarrhea N/A
Completed NCT01814202 - Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea N/A
Completed NCT02896465 - Human Milk Oligosaccharides and Childhood Diarrhoea N/A
Completed NCT01927094 - Effects of Probiotics and/or Prebiotics on the Duration of Diarrhea and Hospitalization in Children Phase 4
Completed NCT04796480 - Comparison Of Outcome Of Lactose Free Formula Milk With Yogurt In Children With Acute Diarrhea N/A
Completed NCT01571856 - Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Phase 4
Completed NCT01269892 - Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea Phase 2
Completed NCT00429325 - Fecal Calprotectin: Cheap Marker for Diagnosing Acute Infectious Diarrhea N/A
Recruiting NCT05183789 - IL6&8 in Malnourished Children With Acute Diarrhea
Completed NCT01564290 - Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children Phase 4
Recruiting NCT05213325 - Evaluation of Serum Interleukin 6 and 8 in Children With Acute Gastroenteritis
Unknown status NCT01273012 - Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital N/A
Completed NCT03356327 - Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea Phase 4